ArticleReviews in obstetrics & gynecology2011
Progesterone supplementation and the prevention of preterm birth.
Article in Reviews in obstetrics & gynecology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 67 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double Blinded, Placebo Controlled Trial of Oral Progestogen Supplementation in the Prevention of Recurrent Uterine Contraction in Preterm Labor
Oral Dydrogesterone as Adjunctive Therapy in the Management of Preterm Labor: A Randomized, Double Blinded, Placebo-controlled Trial
Who cites it
67 citing papers in PubMed, 2 syntheses or guidelines pooled it, 137 citations in OpenAlex.
- Urinary oxidative stress biomarkers are associated with preterm birth: an Environmental Influences on Child Health Outcomes program study.American journal of obstetrics and gynecology · 2023Pooled it
- The Influence of Oral Dydrogesterone and Vaginal Progesterone on Threatened Abortion: A Systematic Review and Meta-Analysis.BioMed research international · 2017Pooled it
- Adjuvant Treatment with Oral Dydrogesterone in the Prevention of Preterm Labor: A Randomized, Double-Blinded, Placebo-Controlled Trial.Reproductive sciences (Thousand Oaks, Calif.) · 2023Trial
- Comparison of oral Dydrogesterone and 17-α hydroxyprogesterone caprate in the prevention of preterm birth.BMC pregnancy and childbirth · 2022Trial
- Oral dydrogesterone as an adjunctive therapy in the management of preterm labor: a randomized, double blinded, placebo-controlled trial.BMC pregnancy and childbirth · 2021Trial
- Thermal-enhanced self-heating microneedle patch for sustained progesterone delivery and improved pregnancy maintenance.Materials today. Bio · 2026Article
- ASC-Derived Extracellular Vesicles Suppress Macrophage-Driven Inflammatory Amplification and Contractile Activation of Uterine Smooth Muscle Cells.International journal of molecular sciences · 2026Article
- Secular trend of gestational diabetes mellitus and its interaction effect with advanced maternal age on adverse maternal-perinatal outcomes among primiparous singleton and twin pregnancies in Hubei, China (2011-2019).Frontiers in endocrinology · 2025Article
- Contractile responses of engineered humanAPL bioengineering · 2024Article
- Microbiome preterm birth DREAM challenge: Crowdsourcing machine learning approaches to advance preterm birth research.Cell reports. Medicine · 2024Article
- Systems biology approach: identification of hub genes, signaling pathways, and molecular docking of COL1A1 gene in cervical insufficiency.In silico pharmacology · 2024Article
- Unravelling the genetic landscape of cervical insufficiency: Insights into connective tissue dysfunction and hormonal pathways.PloS one · 2024Article
- Effects of Prenatal Exposure to Bisphenol A Substitutes, Bisphenol S and Bisphenol F, on Offspring's Health: Evidence from Epidemiological and Experimental Studies.Biomolecules · 2023Review
- Progesterone-mediated reversal of mifepristone-induced pregnancy termination in a rat model: an exploratory investigation.Scientific reports · 2023Article
- Microbiome Preterm Birth DREAM Challenge: Crowdsourcing Machine Learning Approaches to Advance Preterm Birth Research.medRxiv : the preprint server for health sciences · 2023Article
- Preterm Birth, Developmental Smoke/Nicotine Exposure, and Life-Long Pulmonary Sequelae.Children (Basel, Switzerland) · 2023Review
- Cervicovaginal mucus barrier properties during pregnancy are impacted by the vaginal microbiome.Frontiers in cellular and infection microbiology · 2023Article
- Regulation of oxytocin-induced calcium transients and gene expression in engineered myometrial tissues by tissue architecture and matrix rigidity.Current research in physiology · 2023Article
- Approach to ovarian torsion with corpus luteum re-moval in early pregnancy.Qatar medical journal · 2023Article
- A dual-binding magnetic immunoassay to predict spontaneous preterm birth.Frontiers in bioengineering and biotechnology · 2023Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preterm birth is currently the most important problem in maternal-child health in the United States and possibly throughout the world. It complicates one in eight US deliveries, and accounts for over 85% of all perinatal morbidity and mortality. Although survival of preterm infants has increased steadily over the past four decades-due in large part to the use of antenatal corticosteroids, improvements in neonatal resuscitation, and the introduction of neonatal intensive care units-efforts to prevent preterm birth have been largely unsuccessful. On February 3, 2011, the US Food and Drug Administration (FDA) approved the use of progesterone supplementation (hydroxyprogesterone caproate) during pregnancy to reduce the risk of recurrent preterm birth in women with a history of at least one prior spontaneous preterm delivery. This is the first time that the FDA has approved a medication for the prevention of preterm birth, and represents the first approval of a drug specifically for use in pregnancy in almost 15 years. This article reviews the evidence behind the use of progesterone for the prevention of preterm birth, and provides guidelines for the use of progesterone supplementation in clinical practice. A number of areas of ongoing controversy are addressed, including the optimal formulation and route of administration, the safety of progesterone supplementation in pregnancy, and its proposed mode of action.
Indexed as
Identifiers
22102929PMC3218546W1598179263What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.